

Evitrade Supports Canadian Senate Vote on Marijuana Legalization

VANCOUVER, BC, Friday June 8, 2018 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: AXHLF) (the "Company") announces that it welcomes and supports the Canadian Senate and their approval of Bill C-45 for the pending legalization of recreational marijuana laws for the country.

"The Company is pleased over the support that the Canadian Senate has shown for the direction of the cannabis laws for the country" said CEO C.K. "As the Company moves ahead with its development of technology and biomedical systems that improve the human condition, we see a unique fit with some of our technology and its use in the medical and recreational cannabis industries."

The company recently announced a Letter of Intent with Cantech Molecular Research Inc. whose focus is on the development of haploid breeding protocols for plants that will enable the delivery of consistent and predictable biologics at each and every growth cycle. "Utilizing Cantech's technology in scientific breeding of plants in the medical and recreational cannabis space is a true win for the sector and a needed support for patient comfort and product reliability" continued C.K.

Management continues to strive to seek optimal business and commercialization strategies for the Company, including the recent acquisition of Artillery Labs and other opportunities currently being pursued. This, with the continued relationship with Haywood Securities as financial advisor, has the Company planning forward for a bright future.

Contact: C.K. Cheung, CEO

EVITRADE Health Systems Corporation (formerly Auxellence Health Corporation) Email <u>info@evahealthsystems.com</u> Website http://www.evahealthsystems.com CSE Micro-site: <u>http://thecse.com/en/listings/technology/evitrade-health-systems-corp</u> US OTC Markets: http://www.otcmarkets.com/stock/AXHLF/news



About EVITRADE Health (CSE: EVA, OTCQB: AXHLF)

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online "digital healthcare" services for resolving common health problems. The current markets are weight-management, high blood pressure, high blood glucose and heart arrhythmia.

Disclaimers – Forward Looking Statements

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, http://thecse.com/en/listings/technology/evitrade-health-systems-corp, http://thecse.com/en/listings/technology/evitrade-health-systems-corp, http://thecse.com/en/listings/technology/evitrade-health-systems-corp, and http://www.otcmarkets.com/stock/AXHLF/filings. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the

Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.